健身气功防治COPD稳定期患者的临床观察及机理的研究
|
摘要
目的：本文从系统文献的理论研究及临床研究两方面验证健身气功养肺处方对COPD稳定期患者的防治作用,并进一步探讨其发挥作用的机理。
方法：
本研究选用2008年10月—2010年10月期间江苏省省级机关医院门诊及病房出院后符合2007年《慢性阻塞性肺疾病诊治指南标准》中诊断标准及分级标准中Ⅰ级和Ⅱ级COPD稳定期患者118例作为实验对象,其中,Ⅰ级患者57例,随机分为对照1组17例,对照2组15例,实验组25例。三组均不服用药物,对照2组执行缩唇呼吸+步行处方,实验组执行健身气功养肺处方。Ⅱ级患者61例,随机分为对照1组18例,对照2组17例,实验组26例。三组均服用药物舒利迭,对照2组在服用药物基础上执行缩唇呼吸+步行处方,实验组在服用药物基础上,加练健身气功养肺处方。执行处方时间为6个月,观察经过6个月健身气功养肺处方治疗前后肺功能、运动耐力、临床症状积分、生活质量评分、动脉血气分析、急性发作次数、疗效、用药量变化、不良反应等指标的变化情况。
结果：
Ⅰ级患者：
1)三组在实验前后FEV1(%)及FEV1/FVC(％)比较无明显差异,组间比较无差异。
2)对照1组在实验前后6min步行距离无差异；对照2组及实验组实验后与实验前比较有明显差异,与对照1组组间比较有明显差异。
3)对照1组在实验前后临床症状积分无差异；对照2组实验后与实验前比较咳嗽、咳痰、喘息、气短症状积分明显下降；自汗、易感冒、哮鸣音症状积分无差异;与对照1组组间比较喘息、气短症状积分明显下降；咳嗽症状积分有下降；咳痰、自汗、易感冒、哮鸣音症状积分无差异。实验组实验后与实验前比较咳嗽、咳痰、喘息、易感冒、气短症状积分明显下降；自汗、哮鸣音症状积分无改变；与对照1组组间比较喘息、易感冒症状积分明显下降；咳嗽、气短症状积分有下降；咳痰、自汗、哮鸣音症状积分无差异；与对照2组组间比较易感冒症状积分明显下降。
4)对照1组生活质量评分实验后与实验前比较无差异。对照2组日常生活能力、焦虑心理症状评分与实验前比较评分有明显下降；抑郁心理症状与实验前比较评分有下降；社会活动项目评分与实验前比较无统计学意义。与对照1组组间比较焦虑心理症状评分有下降,其它无差异。实验组生活质量评分中日常生活能力、焦虑心理症状、抑郁心理症状与实验前比较评分有明显下降;社会活动项目评分与实验前比较无统计学意义。实验后与对照1组组间比较焦虑心理症状有显著差异,日常生活能力、抑郁心理症状有差异；与对照2组组间比较无差异。三组实验前组间比较无差异。
5)对照1组实验后PaO2、PaC02与实验前比较无差异；对照2组实验后与实验前比较PaO2明显上升,PaCO2无差异；与对照1组组间比较PaO2上升,PaCO2无差异。实验组实验后与实验前比较PaO2明显上升,PaCO2无差异;与对照1组组间比较PaO2上升,PaCO2无差异；与对照2组组间比较无差异。
6)对照1组实验前后急性发作次数比较无差异；对照2组实验前后急性发作次数比较无差异；实验组实验前后急性发作次数比较有差异。
7)综合疗效三组实验后比较无差异,中医症候疗效实验后比较：对照2组与对照1组有明显差异；实验组与对照1组有明显差异；实验组与对照2组无差异。
8)三组患者的肿瘤坏死因子、白细胞介素-8、白细胞介素-6指标变化比较无论是实验前后对比还是组间对比均无差异。
Ⅱ级患者：
1)三组在实验后与实验前比较FEV1(%)及FEV1/FVC(%)均明显上升,实验前后组间比较均无差异。
2)对照1组实验后与实验前比较6min步行距离有明显升高；对照2组实验后与实验前比较6min步行距离有明显升高,与对照1组组间比较有升高；实验组实验后与实验前比较6min步行距离有明显升高；与与对照1组组间比较有升高,与对照2组组间比较无差异。实验前各组组间比较无差异。
3)对照1组实验后与实验前比较：咳嗽、气短症状积分明显下降；喘息、易感冒症状积分有下降。对照2组实验后与实验前比较：咳嗽、自汗症状积分明显下降；喘息、易感冒、气短症状积分有下降。实验组实验后与实验前比较：咳嗽、喘息、易感冒、气短症状积分明显下降。
4)对照1组生活质量评分实验后与实验前比较：日常生活能力评分明显下降,其它无统计学意义。对照2组生活质量评分实验后与实验前比较：日常生活能力评分明显下降,其它无统计学意义。实验组生活质量评分实验后与实验前比较：日常生活能力、焦虑心理症状评分明显下降,抑郁心理症状评分有下降；与对照1组组间比较日常生活能力评分明显下降,抑郁心理症状评分有下降,其它无变化。实验前组间比较无差异。
5)对照1组实验后与实验前比较：PaO2无差异,PaCO2有下降。对照2组实验后与实验前比较：PaO2有升高,PaCO2有下降。实验组实验后与实验前比较：PaO2有升高,PaCO2有明显下降。实验前后组间比较无差异。
6)三组实验后与实验前比较急性发作次数均有差异。
7)三组在实验后综合疗效及中医症候疗效比较均无差异。
8)用药量实验后对照2组与对照1组比较有减少,实验组与对照1组比较有减少；实验组与对照2组比较无差异。
9)对照1组实验后与实验前比较肿瘤坏死因子、白细胞介素-8、白细胞介素-6均有下降,对照2组实验后与实验前比较：肿瘤坏死因子、白细胞介素-8有明显下降,白细胞介素-6均有下降；与对照1组组间比较无差异。实验组实验后与实验前比较：肿瘤坏死因子、白细胞介素-8有明显下降,白细胞介素-6有下降；与对照1组组间比较肿瘤坏死因子有下降,其它无差异。实验前各组组间比较无差异。
结论：(1)慢性阻塞性肺疾病属于中医“咳嗽、喘证、肺胀”等范畴,早期临床表现与中医学中的咳嗽相似,随着病情的发展,肺功能损伤的进一步加重,临床表现与喘证类似,当疾病进一步发展,表现为严重肺气肿或肺心病时,临床表现即为中医肺胀的范畴。(2)对于慢性阻塞性肺疾病稳定期的防治应以固本为主,即补益肺脾肾之虚衰以固其本。(3)健身气功养肺处方对慢性阻塞性肺疾病的发生具有良好的预防和辅助治疗作用,是一种简便易行、有效并适宜推广的肺康复方法；(4)健身气功养肺处方是通过调神、气功态呼吸方法、属中小强度的有氧运动、对肺、脾、肾等脏的调节、“三调”合一等方面对慢性阻塞性肺疾病起到较好的防治作用。
Objective:To make the verification of therapeutic efficiency on Chinese Health Qigong Lung Prescription treating patients with stable COPD through a systematic literature review and clinical research,and further explore the mechanism of its role.
Method:
The subjects was came from Provincial Authorities of Jiangsu Province in October 2008 to October 2010 during the month of outpatient and hospital wards after discharge line with 2007, "Diagnosis and treatment of chronic obstructive pulmonary disease guidelines standards " in the standard diagnostic criteria and classification of gradeⅠandⅡ118 cases of patients with stable COPD. Which,Ⅰgrade were randomly divided into control group 1 in 17 cases,15 cases were 2, the experimental group of 25 patients. Three groups are not taking the drugs, the implementation of the control group 2 reduced lip breathing + walking prescription, the experimental group perform Chinese Health Qigong Lung Prescription prescription. GradeⅡ61 patients were randomly divided into control a group of 18 patients,17 patients in control group 2, the experimental group 26 cases. Three groups were taking medication Seretide, control group 2 drugs on the basis of the implementation of reduced lip breathing + walking prescription, the experimental group on the basis of taking the drug, plus practicing Chinese Health Qigong Lung Prescription prescription. The implementation of prescriptions for 6 months, and observed after 6 months of treatment before and after Chinese Health Qigong Lung Prescription pulmonary function, exercise capacity, clinical symptom scores, quality of life score, arterial blood gas analysis, the number of acute onset, efficacy, dosage changes, adverse reactions Changes in other indicators.
Result:
Grade I:
1)There was no difference between three groups before and after experiment on FEV1 (%) and FEV1/FVC (%) no significant difference between the two groups no difference.
2)Control group 1 before and after the 6min walking distance of the experiment no difference; the control group and experimental group 2 and experimental before and after the experiment were significantly different, with the control group 1 were significantly different between groups.
3)Control group 1 before and after the experiment was no difference in clinical symptom score; the control and experimental group 2 before and after the experiment cough, sputum, wheezing, shortness of breath symptom scores decreased significantly; spontaneous, easy cold, wheeze was no difference in symptom score; and control Group 1 between the two groups breathing, shortness of breath symptom scores decreased significantly; cough symptom score had decreased; sputum, spontaneous, easy cold, wheeze was no difference in symptom scores. Experimental group before and after the experiment and experimental cough, sputum, wheezing, easy to cold, shortness of breath symptom scores decreased significantly; spontaneous, wheeze symptom scores did not change; with the control group 1 between the two groups breathing, easy cold symptom scores decreased significantly; cough, shortness of breath symptom score had decreased; sputum, spontaneous, wheeze was no difference in symptom score; and control group 2 between the two groups easy cold symptom scores decreased significantly.
4) Quality of life scores in control group 1 and experimental before and after the experiment was no different. Control group 2 activities of daily living and anxiety symptom scores compared with scores before the experiment significantly decreased; psychological symptoms of depression compared with rates before the experiment to decrease; social activities scores were not significantly before the experiment. With the control group 1 between the two groups have decreased anxiety symptom scores, the other no difference. Quality of life scores in the experimental group, activities of daily living, anxiety symptoms, depressive symptoms and psychological test scores were significantly decreased compared with that before; social activities scores were not significantly before the experiment. After the experiment group and control group 1 between the psychological symptoms of anxiety were significantly different, daily living skills, psychological symptoms of depression are different; with the control group 2 no significant difference between the two groups. Three groups before the experiment was no difference between the two groups.
5) Control group 1 after the experiment PaO2, PaCO2 and no difference before the experiment; the control and experimental group 2 before and after the experiment significantly increased PaO2, PaCO2 no difference; with the control group 1 between the two groups increased PaO2, PaCO2 no difference. Experimental group before and after the experiment and the experiment significantly increased PaCCO2 no difference; with the control group 1 between the two groups increased PaCO2, PaCCO2 no difference; with the control group 2 no significant difference between the two groups.
6) The control group 1 before and after experiment no difference between the number of acute attacks; control group 2 before and after the experiment was no difference between the number of acute attacks; the experimental group compared before and after experiment with different number of acute attack.
7) After three sets of experiments Integrated efficacy was no difference in efficacy of TCM symptoms comparison experiment:the control group 2 and control group 1 were significantly different; the experimental group and control group 1 were significantly different; the experimental group and control group 2 was no different.
8) Three groups of tumor necrosis factor, interleukin -8, interleukin -6 indexes in both experiments before and after comparison or contrast there was no difference between the groups.
Grade II
1) Three groups before and after the experiment and experimental FEV1 (%) and FEV1/FVC (%) were significantly increased, there was no experimental difference between the two groups before and after.
2) The control group 1 before and after the experiment 6min walk distance significantly increased; the control and experimental group 2 before and after the experiment 6min walk distance increased significantly with the control group 1 between the two groups had elevated; the experimental group and after the experiment 6min walk distance compared before the experiment significantly increased; and with the control group 1 group increased compared with the control group 2 no significant difference between the two groups. Each group before the experiment was no difference between the two groups.
3) The control group 1 before and after the experiment:cough, shortness of breath symptom scores decreased significantly; wheezing, easy integration to decrease cold symptoms. Control and experimental group 2 before and after the experiment: cough, spontaneous symptom scores decreased significantly; wheezing, easy to cold, shortness of breath symptom scores have decreased. Experimental group before and after the experiment and the experiment:coughing, wheezing, easy to cold, shortness of breath symptom scores decreased significantly
4) Quality of life scores in control group 1 and experimental before and after the experiment:activities of daily living score was significantly decreased, the other not statistically significant. Control group 2 quality of life scores before and after the experiment and the experiment:activities of daily living score was significantly decreased, the other not statistically significant. Experimental group, the quality of life scores before and after the experiment and the experiment:daily living, symptom score decreased anxiety, depression and psychological symptom score had decreased; with the control group 1 between the two groups significantly decreased activities of daily living scores, psychological symptom score had decreased depression Other unchanged. Before the experiment was no difference between the two groups.
5) Control group 1 before and after the experiment:PaO2 no difference, PaCO2 had decreased. Control and experimental group 2 before and after the experiment: PaO2 has increased, PaCO2 had decreased. Experimental group before and after the experiment and the experiment:PaO2 had increased, PaCO2 decreased significantly. Before and after experiment no difference between the two groups.
6) Three groups before and after the experiment and the experimental number of acute attack are different.
7) Three integrated effect and after the experiment showed no difference in efficacy of traditional Chinese medicine symptoms.
8) Dosage experiment in control group 2 compared with the control group 1 decreased in the experimental group compared with the control group 1 decreased; the experimental group and control group 2 showed no difference.
9) Control group 1 before and after the experiment and experimental tumor necrosis factor, interleukin -8, interleukin -6 were decreased in the control and experimental group 2 before and after the experiment:tumor necrosis factor, interleukin -8 decreased significantly, IL-6 were decreased; and control group 1 no significant difference between the two groups. Experimental group before and after the experiment and the experiment:tumor necrosis factor, interleukin -8 have significantly decreased, a decreasing interleukin-6; with the control group 1 between the two groups of tumor necrosis factor has dropped, the other no difference. Each group before the experiment was no difference between the two groups.
Conclusion:
(1) Chronic obstructive pulmonary diseases are among the Chinese, "cough, asthma card, lung inflation " and other areas, and in early clinical manifestations similar to cough medicine, as the disease progresses, further aggravating lung injury, clinical manifestations and asthma Card similar to the further development when the disease, manifested as severe emphysema or pulmonary heart disease, the clinical manifestations of lung inflation is the scope of traditional Chinese medicine. (2) for chronic obstructive pulmonary disease prevention and control should be based on coupon-based, that benefit of the virtual failure of lung, spleen and kidney to its present solid. (3) Chinese Health Qigong Lung Prescription for chronic obstructive pulmonary disease with good prevention and adjuvant therapy, is a simple, effective and appropriate ways to promote pulmonary rehabilitation; (4) Chinese Health Qigong Lung Prescription By adjusting God, qigong breathing state, is a medium intensity aerobic exercise, lung, spleen, kidney and other dirty regulation, the "three tune " One and other aspects of chronic obstructive pulmonary disease prevention and control play a better role.
方法：
本研究选用2008年10月—2010年10月期间江苏省省级机关医院门诊及病房出院后符合2007年《慢性阻塞性肺疾病诊治指南标准》中诊断标准及分级标准中Ⅰ级和Ⅱ级COPD稳定期患者118例作为实验对象,其中,Ⅰ级患者57例,随机分为对照1组17例,对照2组15例,实验组25例。三组均不服用药物,对照2组执行缩唇呼吸+步行处方,实验组执行健身气功养肺处方。Ⅱ级患者61例,随机分为对照1组18例,对照2组17例,实验组26例。三组均服用药物舒利迭,对照2组在服用药物基础上执行缩唇呼吸+步行处方,实验组在服用药物基础上,加练健身气功养肺处方。执行处方时间为6个月,观察经过6个月健身气功养肺处方治疗前后肺功能、运动耐力、临床症状积分、生活质量评分、动脉血气分析、急性发作次数、疗效、用药量变化、不良反应等指标的变化情况。
结果：
Ⅰ级患者：
1)三组在实验前后FEV1(%)及FEV1/FVC(％)比较无明显差异,组间比较无差异。
2)对照1组在实验前后6min步行距离无差异；对照2组及实验组实验后与实验前比较有明显差异,与对照1组组间比较有明显差异。
3)对照1组在实验前后临床症状积分无差异；对照2组实验后与实验前比较咳嗽、咳痰、喘息、气短症状积分明显下降；自汗、易感冒、哮鸣音症状积分无差异;与对照1组组间比较喘息、气短症状积分明显下降；咳嗽症状积分有下降；咳痰、自汗、易感冒、哮鸣音症状积分无差异。实验组实验后与实验前比较咳嗽、咳痰、喘息、易感冒、气短症状积分明显下降；自汗、哮鸣音症状积分无改变；与对照1组组间比较喘息、易感冒症状积分明显下降；咳嗽、气短症状积分有下降；咳痰、自汗、哮鸣音症状积分无差异；与对照2组组间比较易感冒症状积分明显下降。
4)对照1组生活质量评分实验后与实验前比较无差异。对照2组日常生活能力、焦虑心理症状评分与实验前比较评分有明显下降；抑郁心理症状与实验前比较评分有下降；社会活动项目评分与实验前比较无统计学意义。与对照1组组间比较焦虑心理症状评分有下降,其它无差异。实验组生活质量评分中日常生活能力、焦虑心理症状、抑郁心理症状与实验前比较评分有明显下降;社会活动项目评分与实验前比较无统计学意义。实验后与对照1组组间比较焦虑心理症状有显著差异,日常生活能力、抑郁心理症状有差异；与对照2组组间比较无差异。三组实验前组间比较无差异。
5)对照1组实验后PaO2、PaC02与实验前比较无差异；对照2组实验后与实验前比较PaO2明显上升,PaCO2无差异；与对照1组组间比较PaO2上升,PaCO2无差异。实验组实验后与实验前比较PaO2明显上升,PaCO2无差异;与对照1组组间比较PaO2上升,PaCO2无差异；与对照2组组间比较无差异。
6)对照1组实验前后急性发作次数比较无差异；对照2组实验前后急性发作次数比较无差异；实验组实验前后急性发作次数比较有差异。
7)综合疗效三组实验后比较无差异,中医症候疗效实验后比较：对照2组与对照1组有明显差异；实验组与对照1组有明显差异；实验组与对照2组无差异。
8)三组患者的肿瘤坏死因子、白细胞介素-8、白细胞介素-6指标变化比较无论是实验前后对比还是组间对比均无差异。
Ⅱ级患者：
1)三组在实验后与实验前比较FEV1(%)及FEV1/FVC(%)均明显上升,实验前后组间比较均无差异。
2)对照1组实验后与实验前比较6min步行距离有明显升高；对照2组实验后与实验前比较6min步行距离有明显升高,与对照1组组间比较有升高；实验组实验后与实验前比较6min步行距离有明显升高；与与对照1组组间比较有升高,与对照2组组间比较无差异。实验前各组组间比较无差异。
3)对照1组实验后与实验前比较：咳嗽、气短症状积分明显下降；喘息、易感冒症状积分有下降。对照2组实验后与实验前比较：咳嗽、自汗症状积分明显下降；喘息、易感冒、气短症状积分有下降。实验组实验后与实验前比较：咳嗽、喘息、易感冒、气短症状积分明显下降。
4)对照1组生活质量评分实验后与实验前比较：日常生活能力评分明显下降,其它无统计学意义。对照2组生活质量评分实验后与实验前比较：日常生活能力评分明显下降,其它无统计学意义。实验组生活质量评分实验后与实验前比较：日常生活能力、焦虑心理症状评分明显下降,抑郁心理症状评分有下降；与对照1组组间比较日常生活能力评分明显下降,抑郁心理症状评分有下降,其它无变化。实验前组间比较无差异。
5)对照1组实验后与实验前比较：PaO2无差异,PaCO2有下降。对照2组实验后与实验前比较：PaO2有升高,PaCO2有下降。实验组实验后与实验前比较：PaO2有升高,PaCO2有明显下降。实验前后组间比较无差异。
6)三组实验后与实验前比较急性发作次数均有差异。
7)三组在实验后综合疗效及中医症候疗效比较均无差异。
8)用药量实验后对照2组与对照1组比较有减少,实验组与对照1组比较有减少；实验组与对照2组比较无差异。
9)对照1组实验后与实验前比较肿瘤坏死因子、白细胞介素-8、白细胞介素-6均有下降,对照2组实验后与实验前比较：肿瘤坏死因子、白细胞介素-8有明显下降,白细胞介素-6均有下降；与对照1组组间比较无差异。实验组实验后与实验前比较：肿瘤坏死因子、白细胞介素-8有明显下降,白细胞介素-6有下降；与对照1组组间比较肿瘤坏死因子有下降,其它无差异。实验前各组组间比较无差异。
结论：(1)慢性阻塞性肺疾病属于中医“咳嗽、喘证、肺胀”等范畴,早期临床表现与中医学中的咳嗽相似,随着病情的发展,肺功能损伤的进一步加重,临床表现与喘证类似,当疾病进一步发展,表现为严重肺气肿或肺心病时,临床表现即为中医肺胀的范畴。(2)对于慢性阻塞性肺疾病稳定期的防治应以固本为主,即补益肺脾肾之虚衰以固其本。(3)健身气功养肺处方对慢性阻塞性肺疾病的发生具有良好的预防和辅助治疗作用,是一种简便易行、有效并适宜推广的肺康复方法；(4)健身气功养肺处方是通过调神、气功态呼吸方法、属中小强度的有氧运动、对肺、脾、肾等脏的调节、“三调”合一等方面对慢性阻塞性肺疾病起到较好的防治作用。
Objective:To make the verification of therapeutic efficiency on Chinese Health Qigong Lung Prescription treating patients with stable COPD through a systematic literature review and clinical research,and further explore the mechanism of its role.
Method:
The subjects was came from Provincial Authorities of Jiangsu Province in October 2008 to October 2010 during the month of outpatient and hospital wards after discharge line with 2007, "Diagnosis and treatment of chronic obstructive pulmonary disease guidelines standards " in the standard diagnostic criteria and classification of gradeⅠandⅡ118 cases of patients with stable COPD. Which,Ⅰgrade were randomly divided into control group 1 in 17 cases,15 cases were 2, the experimental group of 25 patients. Three groups are not taking the drugs, the implementation of the control group 2 reduced lip breathing + walking prescription, the experimental group perform Chinese Health Qigong Lung Prescription prescription. GradeⅡ61 patients were randomly divided into control a group of 18 patients,17 patients in control group 2, the experimental group 26 cases. Three groups were taking medication Seretide, control group 2 drugs on the basis of the implementation of reduced lip breathing + walking prescription, the experimental group on the basis of taking the drug, plus practicing Chinese Health Qigong Lung Prescription prescription. The implementation of prescriptions for 6 months, and observed after 6 months of treatment before and after Chinese Health Qigong Lung Prescription pulmonary function, exercise capacity, clinical symptom scores, quality of life score, arterial blood gas analysis, the number of acute onset, efficacy, dosage changes, adverse reactions Changes in other indicators.
Result:
Grade I:
1)There was no difference between three groups before and after experiment on FEV1 (%) and FEV1/FVC (%) no significant difference between the two groups no difference.
2)Control group 1 before and after the 6min walking distance of the experiment no difference; the control group and experimental group 2 and experimental before and after the experiment were significantly different, with the control group 1 were significantly different between groups.
3)Control group 1 before and after the experiment was no difference in clinical symptom score; the control and experimental group 2 before and after the experiment cough, sputum, wheezing, shortness of breath symptom scores decreased significantly; spontaneous, easy cold, wheeze was no difference in symptom score; and control Group 1 between the two groups breathing, shortness of breath symptom scores decreased significantly; cough symptom score had decreased; sputum, spontaneous, easy cold, wheeze was no difference in symptom scores. Experimental group before and after the experiment and experimental cough, sputum, wheezing, easy to cold, shortness of breath symptom scores decreased significantly; spontaneous, wheeze symptom scores did not change; with the control group 1 between the two groups breathing, easy cold symptom scores decreased significantly; cough, shortness of breath symptom score had decreased; sputum, spontaneous, wheeze was no difference in symptom score; and control group 2 between the two groups easy cold symptom scores decreased significantly.
4) Quality of life scores in control group 1 and experimental before and after the experiment was no different. Control group 2 activities of daily living and anxiety symptom scores compared with scores before the experiment significantly decreased; psychological symptoms of depression compared with rates before the experiment to decrease; social activities scores were not significantly before the experiment. With the control group 1 between the two groups have decreased anxiety symptom scores, the other no difference. Quality of life scores in the experimental group, activities of daily living, anxiety symptoms, depressive symptoms and psychological test scores were significantly decreased compared with that before; social activities scores were not significantly before the experiment. After the experiment group and control group 1 between the psychological symptoms of anxiety were significantly different, daily living skills, psychological symptoms of depression are different; with the control group 2 no significant difference between the two groups. Three groups before the experiment was no difference between the two groups.
5) Control group 1 after the experiment PaO2, PaCO2 and no difference before the experiment; the control and experimental group 2 before and after the experiment significantly increased PaO2, PaCO2 no difference; with the control group 1 between the two groups increased PaO2, PaCO2 no difference. Experimental group before and after the experiment and the experiment significantly increased PaCCO2 no difference; with the control group 1 between the two groups increased PaCO2, PaCCO2 no difference; with the control group 2 no significant difference between the two groups.
6) The control group 1 before and after experiment no difference between the number of acute attacks; control group 2 before and after the experiment was no difference between the number of acute attacks; the experimental group compared before and after experiment with different number of acute attack.
7) After three sets of experiments Integrated efficacy was no difference in efficacy of TCM symptoms comparison experiment:the control group 2 and control group 1 were significantly different; the experimental group and control group 1 were significantly different; the experimental group and control group 2 was no different.
8) Three groups of tumor necrosis factor, interleukin -8, interleukin -6 indexes in both experiments before and after comparison or contrast there was no difference between the groups.
Grade II
1) Three groups before and after the experiment and experimental FEV1 (%) and FEV1/FVC (%) were significantly increased, there was no experimental difference between the two groups before and after.
2) The control group 1 before and after the experiment 6min walk distance significantly increased; the control and experimental group 2 before and after the experiment 6min walk distance increased significantly with the control group 1 between the two groups had elevated; the experimental group and after the experiment 6min walk distance compared before the experiment significantly increased; and with the control group 1 group increased compared with the control group 2 no significant difference between the two groups. Each group before the experiment was no difference between the two groups.
3) The control group 1 before and after the experiment:cough, shortness of breath symptom scores decreased significantly; wheezing, easy integration to decrease cold symptoms. Control and experimental group 2 before and after the experiment: cough, spontaneous symptom scores decreased significantly; wheezing, easy to cold, shortness of breath symptom scores have decreased. Experimental group before and after the experiment and the experiment:coughing, wheezing, easy to cold, shortness of breath symptom scores decreased significantly
4) Quality of life scores in control group 1 and experimental before and after the experiment:activities of daily living score was significantly decreased, the other not statistically significant. Control group 2 quality of life scores before and after the experiment and the experiment:activities of daily living score was significantly decreased, the other not statistically significant. Experimental group, the quality of life scores before and after the experiment and the experiment:daily living, symptom score decreased anxiety, depression and psychological symptom score had decreased; with the control group 1 between the two groups significantly decreased activities of daily living scores, psychological symptom score had decreased depression Other unchanged. Before the experiment was no difference between the two groups.
5) Control group 1 before and after the experiment:PaO2 no difference, PaCO2 had decreased. Control and experimental group 2 before and after the experiment: PaO2 has increased, PaCO2 had decreased. Experimental group before and after the experiment and the experiment:PaO2 had increased, PaCO2 decreased significantly. Before and after experiment no difference between the two groups.
6) Three groups before and after the experiment and the experimental number of acute attack are different.
7) Three integrated effect and after the experiment showed no difference in efficacy of traditional Chinese medicine symptoms.
8) Dosage experiment in control group 2 compared with the control group 1 decreased in the experimental group compared with the control group 1 decreased; the experimental group and control group 2 showed no difference.
9) Control group 1 before and after the experiment and experimental tumor necrosis factor, interleukin -8, interleukin -6 were decreased in the control and experimental group 2 before and after the experiment:tumor necrosis factor, interleukin -8 decreased significantly, IL-6 were decreased; and control group 1 no significant difference between the two groups. Experimental group before and after the experiment and the experiment:tumor necrosis factor, interleukin -8 have significantly decreased, a decreasing interleukin-6; with the control group 1 between the two groups of tumor necrosis factor has dropped, the other no difference. Each group before the experiment was no difference between the two groups.
Conclusion:
(1) Chronic obstructive pulmonary diseases are among the Chinese, "cough, asthma card, lung inflation " and other areas, and in early clinical manifestations similar to cough medicine, as the disease progresses, further aggravating lung injury, clinical manifestations and asthma Card similar to the further development when the disease, manifested as severe emphysema or pulmonary heart disease, the clinical manifestations of lung inflation is the scope of traditional Chinese medicine. (2) for chronic obstructive pulmonary disease prevention and control should be based on coupon-based, that benefit of the virtual failure of lung, spleen and kidney to its present solid. (3) Chinese Health Qigong Lung Prescription for chronic obstructive pulmonary disease with good prevention and adjuvant therapy, is a simple, effective and appropriate ways to promote pulmonary rehabilitation; (4) Chinese Health Qigong Lung Prescription By adjusting God, qigong breathing state, is a medium intensity aerobic exercise, lung, spleen, kidney and other dirty regulation, the "three tune " One and other aspects of chronic obstructive pulmonary disease prevention and control play a better role.
引文
[1]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南[J].中华结核与呼吸杂志,2007,30(1)：8-17.
[2]Vollmer WM, Gislason T, Burney P. Comparison of spirometry criteria for the diagnosis of COPD:results from the BOLD Study. The Bold Collaborative Research Group. F.Eur Respir J.2009 May 21.
[3]American Thoracic Society and European Respiratory Society. ATS/ERS statement on pulmonary rehabilitation[J]. Am J Respir Crit Care Med,2006,173:1390-1413.
[4]American Thoracic Society. Global Initiative for Chronic Obstructive Lung Disease:Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2006)[OL]. http://www.goldcopd.com/Guidelineitem. asp.
[5]Budweiser S.Respiratory muscle training in restrictive thoracic dis- ease[J]. Arch Phys Med Rehabil,2006,87(12):1559-1565.
[6]Global strategy for the diagnosismanagementand prevention of chronic obstructive pulmonary disease (COPD)Available from:http://www-goldcopd-org (2007-12-1).
[7]王震,邱丕相,李志明.从导引图与养生功法的流变探研中国健身气功的本质特征[J].体育科学,2005,7(25)：28-31.
[8]田正鉴,徐幼明,李亚清.慢性阻塞性肺疾病中医病机探微.湖北中医学院学报,2001,3(1)：29-30.
[9]陈晓东.慢性阻塞性肺病稳定期从脾虚血瘀论治探析[J].中医函拦通讯,2000,19(6)：20-21.
[10]李建生.慢性阻塞性肺疾病中医辨证治疗概要[J].河南中医学院学报,2009,7(4)：9-11.
[11]谢健,黄明霞.赵淳教授治疗慢性肺心病急性期经验述要[J].中医药学刊,2004,22(3)：398-399.
[12]吴楠,周玉皆.慢性阻塞性肺疾病急性加重期的中医治疗策略[J].中国中医急症,2006,9(15)：9-11.
[13]贺倩.温肺活血法治疗急性发作期慢性支气管炎103例疗效观察[J].中国中医药科技,2005,11(3)：177-178.
[14]董贤明,孙守平,董长富.葶贝胶囊治疗慢性支气管炎急性发作40例疗效观察[J].疑难病杂志,2003,2(2)：94.
[15]刘金民,晏军.慢性阻塞性肺疾病急性发作期中医治疗体会[J].北京中医药大学学报(中医临床版)2003,6(10)：22.
[16]苑惠清,王洪.参元胶囊对慢性阻塞性肺病高凝状态作用的临床研究[J].中国医药学报,2003,8(6)：15-17.
[17]刘小虹,刘琼.培土生金法在慢性阻塞性肺疾病缓解期的床用研究[J].新中医,2002,34(10)：18.
[18]李艳.中医中药治疗慢性阻塞性肺疾病的临床探讨[J].中国现代药物应用,2009,3(3)：51-53.
[19]王鹏.慢性阻塞性肺部疾病的辨证与治疗[J].新中医,1990,22(3)：54.
[20]陈继婷,朱祝生.辨证分型治疗慢性阻塞性肺病85例[J].陕西中医,2000,10(7)：53-56.
[21]孙子凯,曹世宏.262例慢性阻塞性肺病证治规律探讨[J].南京中医药大学学报,1998,14(1)：13-14.
[22]张颖,李廷谦,王刚,等.痰热清注射液治疗慢性阻塞性肺疾病急性加重期(痰热阻肺证)的随机对照试验[J].中国循证医学杂志,2004,4(5)：300-305.
[23]刘建博,荆小莉,刘小虹.加味千金苇茎汤对慢性阻塞性肺病急性加重期患者气道清除功能的影响[J].广州中医药大学学报,2006,23(1)：21-24.
[24]崔众,梁直英,董竞成.活血化疲方治疗慢性阻塞性肺疾病急性加重期的临床观察[J].中国中西医结合杂志,2005,25(4)：327-329.
[25]林育华.活血化淤法治疗慢阻肺95例临床观察[J].新中医,1998,30(2)：33-34.
[26]孙志佳.活血祛淤法治疗慢性阻塞性肺疾病理论依据及临床应用[J].陕西中医,2005,26(4)：341-342.
[27]王胜,张念志,季红燕,等.益肺健脾中药对慢性阻塞性肺疾病气道炎症作用的研究[J].中国中西医结合杂志,2002,22(6)：462.
[28]刘小虹,刘琼.培土生金法在慢性阻塞性肺疾病缓解期的床用研究[J].新中医,2002,34(10)：18.
[29]汤翠英,林琳,许银姬.培土生金法对慢阻肺稳定期患者生存质量的影响[J].福建中医药,2006：35(5)：1-4.
[30]张炜,毕小利,史苗颜,等.补肺益肾胶囊对慢性阻塞性肺疾病防治作用的研究[J].中国中医基础医学杂志,2004,10(1)：57.
[31]吴晓晖,徐俭朴.百令胶囊治疗肺肾两虚证慢性阻塞性肺病50例[J].实用中医内科杂志,2004,18(4)：351-352.
[32]耿宏伟,胡秀红.金水宝胶囊治疗慢性阻塞性肺疾病60例[J].中医研究,2003 13(4)：46.
[33]Barns PJ. Chronic obstructive pulmonary disease.N Engl J Med 2000;343:269-280.
[33]Altose MD. Approachs to slowing the progression of COPD. Curr Opin Pulm Med 2003;9:125-130.
[34]Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, et al.Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease, Am J Respir Cirt Care Med 2001;163:1087-1092.
[35]MahlerDA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmetero xinafoate in the treatmenty of COPD. Chest 1999; 115:957-965.
[36]Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaked-agonist, and the combination of all three in patients with COPD. Chest 1994;105:1089-1094.
[37]COMBIVENT Inhalation Awrosol Study Group.In chronic obstructive pulmonary disease, a combination of iprtropium and albuterol is more effective than either agent alone An 85-day multicentre trial. Chest 1994; 105:1411-1419.
[38]Wesseling G, Mostert R, Wouters EEM. A comparison of the effects of anticholinergic and beta2-agonist and combination therapy on respiratory impedence in COPD. Chest 1992:101:166-173.
[39]Maesen FPV, Smeets JJ, Costongs MAL, Wald FDM, Coneliseen PJG. Ba 679 Br, a new long-acting antimuscarinic bronchiodilator:a plot disc-esealation study in COPD. Eur Rtespir J 1993:6:1031-1036.
[40]Ress PJ. Tiotropium in the management of chronic obstructive pulmonary disease. Eur Rtespir J2002; 19:205-206.
[41]Birring SS, Brightling CE, Bradding P, et al. Clinical,radiologic,and induced sputum features of chronic obstructive pulmonary disease in nonsmokers:a descriptive study. Am J Respir Cirt Care Med 2002; 166:1078-1083.
[42]Kanner RE, Connett JE, Williams DE, et al. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disese;The Lung Heath Study.Am J Med 1999; 106:410-416.
[43]Smith KR. National burden of disease in India from indoor air pollution.Proc Natl Acad Sci USA 2000; 97:13286-13293.
[44]ShapiroSD. Elastolytic metalloproteinases produced by human mononuclear phago cytes. Potential roles in destructive lung disease. Am J Respir Cirt Care Med 1994; 150:S160-164
[45]Finlary GA, Russell KJ, McMahon KJ, D'arcy EM, Masterson JB, FitzGerald MX, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorac 1997; 52:502-506.
[46]Dehuijzen PN, Aben KK, Dekker I, Aarts LP, Wielders PL,van Herwaarden CL, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstrucetive pulmonary disease. Am J Respir Cirt Care Med 1996; 154:813-816.
[47]Paredi P,Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxi dation, is elevated in chronic obstructive pulmonary desease. Am J Respir Cirt Care Med 2000; 162:369-373.
[48]Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Cirt Care Med 2000; 162:1175-1177.
[49]Pratico D, Basili S, Vieri M, Cordova C, Violi F,Fitzgerald GA. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Cirt Care Med 1998; 158:1709-1714.
[50]O'Donohue WJ Jr. Oxygen therapy in pulmonary rehabilitation. In Hodgkin JE, Celli BR, Connors GL, eds. Pulmonary Rehabilitation:Guidelines to Success. Lippincott Williams and Willkins; 2000:135-146.
[51]Report of the Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1:681-686.
[52]CooperJD. The history of surgical procedures for emphysema. Ann Thorac Surg 1997;63:312-319.
[53]Martinez FJ. Surgical Therapy for COPD. In Hodgkin JE, Celli BR, Connors GL, eds. PulmonaryRehabilitation:Guidelines to Success. Lippincott Williams and Willins,2000:415-451.
[54]Meyers BF, Patterson GA. Chronic obstructive pulmonary disease. lO.Bullectomy, lung volume reduction surgery and transplantation for patients with chronic obstructive pulmonary disease. Thorax 2003;58:634-638.
[55]Edelman JD, Kotloff RM. Surgical approaches to advanced emphysema. Respir Care Clin N Am 1998;4:513-539.
[56]Russi EW, Stammberger U, Weder W. Lung volume reduction surgery for emphysema. Eur Respir J 1997; 10:208-218.
[57]Fessler HE, Permutt S. Lung volume reduction surgery and airflow limitation. Am J Respir Cirt Care Med 1998; 157:715-722.
[58]Gelb AF, Mckenna RJ Jr, Brenner M, Epstein JD, Zamel N. Lung function 5 yr after lung volume reduction surgery for emphy sema. Am J Respir Cirt Care Med 2001; 163:1562-1566.
[59]Mehran RJ, Deslauriers J. Indications for surgery and patient work-up for bullectomy. Chest Surg Clin N Am 1995; 5:717-734.
[60]Trulock EP. Lung transplantation. Am J Respir Cirt Care Med 1997; 155:789-818.
[61]Cassivi SD, Meyers BF, Battafarano RJ, et al. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg 2002; 74:1663-1669.
[62]Barnes PJ. Inhaled corticosteroida are not beneficial in chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2000; 161:341-344.
[63]Calverley PM. Inhaled corticosteroida are beneficial in chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2000; 161:341-342.
[64]Barnes PJ. New treatments for COPD. Nat Rev Drug Discov 2002; 1:437-446.
[65]Barnes PJ. Therapy of chronic obstructive pulmonary disease. Pharmacol Ther 2003; 97:87-94.
[66]HanselTT, BarnesPJ, eds. New Drugs forAsthma, Allergy and COPD. Basel:Karger,2001.
[67]Huang Z, Ducharme Y, MacDonald D, Robichhaud A. The next generation of PDEA inhibitors. Curr OPin Chem Biol 2001; 5:432-438.
[68]Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001:108:671-680.
[69]Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109:288-295.
[70]Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG. Fully human anti-interleukin-8 monoclonal antibodies:potential therapeutice for the treatment of inflammatory disease states. J Leukoc Biol 1999; 66:401-410.
[71]De Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Cirt Care Med 1996; 153:633-637.
[72]Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Cirt Care Med 1996;153:1530-1535.
[73]Pulmonary rehabilitation-1999. American Thoracic Society. Am J Respir Cirt Care Med 1999;159:1666-1682.
[74]Pulmonary rehabilitation. Thorax.2001; 56:827-834.
[75]Buist AS, Sullivan SD, Weiss K, eds. Measurement and evaluation of outcomes in COPD. Eur Respir J 2003;21(Suppl):153s.
[76]Berry MJ, Rejeski WJ, Adair NE, Zaccaro D. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Cirt Care Med 1999; 160:1248-1253.
[77]Miller WF. Historical perspective of pulmonary rehabilitation. In Hodgkin JE, Celli BR, Connors GL, eds. Pulmonary Rehailitation:Guidelines to Success. Baltimore, MD:Lippincott Williams and Wilkins,2000:1-20.
[78]Bott J, Agent P, Callaghan S. Physiotherapy and nursing during non-invasive positive pressure. In Simonds AK, ed. Non-invasive Respiratory Support:a Practical Handbook.New York:Arnold,2001:230-254.
[79]JonesCE, Chan K. Interleukin-17 Stimulates the Expression oflnterleukin-8, Grouth-Related, Oncgeue-a, andGranulocyte-Colony-Stimulating Factor byHuman Airway EpithelialCells [J]. Am JRespirCellMolBiol,2002,26(3):748-753.
[80]Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest,1997; 112(2):505-510.
[81]朱斌,郝建,王伟,等慢性阻塞性肺疾病患者血清细胞因子的变化及其临床意义[J].临床肺科杂志.2008：(12)：17-19.
[82]刘洪,张弛,陈云凤,等.慢性阻塞性肺疾病炎症细胞因子与肺通气功能变化相关分析[J].实用医院临床杂志,2007：1(1)：36-37.
[83]蔡志明.慢性阻塞性肺部疾病-机制的新发展[J].中华内科杂志,2000,39(3)：204-206.
[84]Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med,2007; 176(6):532-555.
[85]丁艳苓.白三烯B4与肺部疾病[J].临床内科杂志,2005,22(11)：790-792.
[86]国家体育总局健身气功管理中心编健身气功·易筋经第一版人民体育出版社,2003.7.
[87]国家体育总局健身气功管理中心编健身气功·八段锦第一版人民体育出版社,2003.7.
[88]国家体育总局健身气功管理中心编健身气功·六字诀第一版人民体育出版社,2003.7.
[89]国家体育总局健身气功管理中心编健身气功·五禽戏第一版人民体育出版社,2003.7.
[90]王震,邱丕相,李志明.从导引图与养生功法的流变探研中国健身气功的本质特征[J].体育科学,2005 25(7)：26-28.
[91]朱毅,李凝,金宏柱.五禽戏早期干预对稳定期慢性阻塞性肺疾病患者的影响[J].辽宁中医药大学学报,2010：6(12)：53-54.
[92]崔永胜,虞定海.“健身气功·五禽戏”锻炼对中老年女性身心健康的影响[J].北京体育大学学报,2004：11(27)：61-63.
[93]陈锦秀,邓丽金.传统“六字诀呼吸操”对COPD稳定期患者的康复效果[J].中国康复医学杂志,200924(10)：32-35.
[94]王振伟,杨佩兰,汤杰等.“六字诀”对慢性阻塞性肺疾病患者生活质量及中医证候的影响[J].上海中医药杂志,2010;44(5)：48.
[95]陈锦秀.传统六字诀呼吸操对慢性阻塞性肺疾病稳定期患者生活质量的效果研究[J].中国自然医学杂志,2009;12(11)：37-38.
[96]冯毅卿,潘华山,泣希等.八段锦运动对慢性阻塞性肺病稳定期老年患者的疗效观察[J].新中医,2009：8(41)：52.
[97]潘华山.八段锦运动负荷对老年人心肺功能影响的研究[J].新中医,2008;1(40)：23-25.
[98]杜少武,章文春,周美芳.健身气功·易筋经锻炼对中老年人体质的影响程度[J].北京体育大学学报,2006：11(29)：39-41.
[99]项汉平,刘树军,贾海等.浅析健身气功易筋经功法特点对呼吸肌的作用[J].北京体育大学学报2006：1(25)：32-35.
[100]冯毅卿,潘华山.八段锦运动对慢性阻塞性肺病稳定期老年患者的疗效观察[J].新中医,2010：5(62)：71.
[101]Clark CJ, Cochrane LM, Mackay E, Paton B. Skeletal muscle strength and endurance in patients with mild COPDand the effects of weight training. Eur Respir J 2000; 15:92-97.
[102]Ortega F, Toral J, Cejudo P, et al. Comparison of effects of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2002; 166:669-674.
[103]Jenkins SC, Heaton RW, Fulton TJ, Moxham J. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest 1987;91:804-807.
[104]Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmetero xinafoate in the treatmenty of COPD. Chest 1999; 115:957-965.
[105]Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmetero xinafoate in the treatmenty of COPD. Chest 1999; 115:957-965.
[106]Suzuki S, Watanuki Y, Yoshiike Y, Okubo T. Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease. Thorax 1997;52:125-129.
[107]Johnson M. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol 2002; 110(Suppl 6):S282-290.
[108]AdcockIM, ManeechotesuwanK, UsmaniO. Molecular interactions between glucocorticoids and long-acting beta2-agonists.J Allergy Clin Immunol 2002; 110(Suppl 6):S261-268.
[109]Mahler DA, The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002; 110(Suppl 6):S298-303.
[110]Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112:336-340.
[111]Guhan AR, Cooper S, Oborne J, Lewis S, Bennett A, Tattersfield AE. Systemic effects of formoterol and salmeterol:a dose-response comparison in healthy subjects.Thorax 2000;55:650-656.
[112]Calverley PM. Inhaled corticosteroida are beneficial in chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2000; 161:341-342.
[113]Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patient after regular use of fluticasone propionate and salmeterol in general practice. Eur Rtespir J 2002;20:819-825.
[114]Sin DD, Tu Inhald corticostercids and the risk of mortility and readmission in elderly patients with chronic obstructibe pulmonary disease. Am J Respir Cirt Care Med 2001;164:341-345.
[115]Barnes PJ. Inhaled corticosteroida are not beneficial in chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2000; 161:341-344.
[116]Rennard SI. COPD:treatments benefit patients.Lancet 2003; 361:444-445.
[117]Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Heath Study Am J Respir Crit Care Med2000,161:381-390.
[118]Fletcher C, Peto R, Tinker CM, Speizer FE. The Natural History of Chronic Bronchitis and Emphysema. New York:Oxford University Press.1976.
[119]Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic ob structive pulmonary disease:the ISOLDE trial. Br Med J 2000;320:1297-1303.
[120]Rochester CL. Exercise training in chronic obstructive pulmonarydisease[J]. Journal of Rehabilitation Research and Development2003,40(5):59-80.
[121]Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacitydynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med2001,163:1395-1399.
[122]Ortega F, Montemayor T, Sanchez A, et al. Role of cardiopulmonary exercise testing and the criteria used to determine disability in patients with severe chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,1994,150(3):747.
[123]Jones PW, Mahler DA. Key outcomes in COPD:heslth-related quality of life. Proceedings of an expert round table held July 20-22,2001,Boston Massachusetts, USA. Eur Respir Rev 2002;12.
[124]Engstrom CP, Presson LO, Larsson S, Sullivan M. Health-relate quality of life in COPD:why both disease-specific and generic measures should be used. Eur Respir J 2001;18:69-76.
[125]Jones PW, Quirk FH, Baveystock CM. The St Grorge's Respiratour Qudetionnaire. Respir Med 1991:85:25-31.
[126]方宗君,蔡映云,蒋浩明,等.SGRQ问卷对慢性阻塞性肺疾病患者生命质量的评估研究[J].中国行医学科学,1996,5：16-17.
[127]陆慰首,张一杰,胡波,等.应用St Gcorgecs呼吸问卷评估我国慢性阻塞性肺疾病患者生存质量的价值[J].华结核和呼吸杂志,2003,26：195-198.
[128]王秋月,王伟等.慢性阻塞性肺疾病患者生活质量及其影响因素分析[J].中华结核和呼吸杂志,2003,12：811-812.
[129]王永兴,应延风.慢性阻塞性肺疾病患者生存质量与肺功能的关系[J].中国临床康复,2002,19：2851-2852.
[130]Belman MJ.Exercise in patients with chronic obstructive pulmonary disease. Thorax 1993;48:436-446.
[131]Mulloy E, McNicholas WT. Ventilation and gas exchange during sleep and exercise in severe COPD. Chest 1996; 109:387-394.
[132]Suzuki S, Watanuki Y, Yoshiike Y, OkuboT. Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease.Thorax 1997;52:125-129.
[133]Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillessen A, et al. Resperatory viruses in exacerbations of chronic obstructive pulmonary disease sequiring hospitalization:a case-control study. Thorax.2003; 58:37-42.
[134]Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med.2001; 134:595-599.
[135]Guhan AR, Cooper S, Oborne J, Lewis S, Bennett A, Tattersfield AE. Systemic effects of formoterol and salmeterol:a dose-response comparison in healthy subjects. Thorax 2000;55:650-656.
[2]Vollmer WM, Gislason T, Burney P. Comparison of spirometry criteria for the diagnosis of COPD:results from the BOLD Study. The Bold Collaborative Research Group. F.Eur Respir J.2009 May 21.
[3]American Thoracic Society and European Respiratory Society. ATS/ERS statement on pulmonary rehabilitation[J]. Am J Respir Crit Care Med,2006,173:1390-1413.
[4]American Thoracic Society. Global Initiative for Chronic Obstructive Lung Disease:Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2006)[OL]. http://www.goldcopd.com/Guidelineitem. asp.
[5]Budweiser S.Respiratory muscle training in restrictive thoracic dis- ease[J]. Arch Phys Med Rehabil,2006,87(12):1559-1565.
[6]Global strategy for the diagnosismanagementand prevention of chronic obstructive pulmonary disease (COPD)Available from:http://www-goldcopd-org (2007-12-1).
[7]王震,邱丕相,李志明.从导引图与养生功法的流变探研中国健身气功的本质特征[J].体育科学,2005,7(25)：28-31.
[8]田正鉴,徐幼明,李亚清.慢性阻塞性肺疾病中医病机探微.湖北中医学院学报,2001,3(1)：29-30.
[9]陈晓东.慢性阻塞性肺病稳定期从脾虚血瘀论治探析[J].中医函拦通讯,2000,19(6)：20-21.
[10]李建生.慢性阻塞性肺疾病中医辨证治疗概要[J].河南中医学院学报,2009,7(4)：9-11.
[11]谢健,黄明霞.赵淳教授治疗慢性肺心病急性期经验述要[J].中医药学刊,2004,22(3)：398-399.
[12]吴楠,周玉皆.慢性阻塞性肺疾病急性加重期的中医治疗策略[J].中国中医急症,2006,9(15)：9-11.
[13]贺倩.温肺活血法治疗急性发作期慢性支气管炎103例疗效观察[J].中国中医药科技,2005,11(3)：177-178.
[14]董贤明,孙守平,董长富.葶贝胶囊治疗慢性支气管炎急性发作40例疗效观察[J].疑难病杂志,2003,2(2)：94.
[15]刘金民,晏军.慢性阻塞性肺疾病急性发作期中医治疗体会[J].北京中医药大学学报(中医临床版)2003,6(10)：22.
[16]苑惠清,王洪.参元胶囊对慢性阻塞性肺病高凝状态作用的临床研究[J].中国医药学报,2003,8(6)：15-17.
[17]刘小虹,刘琼.培土生金法在慢性阻塞性肺疾病缓解期的床用研究[J].新中医,2002,34(10)：18.
[18]李艳.中医中药治疗慢性阻塞性肺疾病的临床探讨[J].中国现代药物应用,2009,3(3)：51-53.
[19]王鹏.慢性阻塞性肺部疾病的辨证与治疗[J].新中医,1990,22(3)：54.
[20]陈继婷,朱祝生.辨证分型治疗慢性阻塞性肺病85例[J].陕西中医,2000,10(7)：53-56.
[21]孙子凯,曹世宏.262例慢性阻塞性肺病证治规律探讨[J].南京中医药大学学报,1998,14(1)：13-14.
[22]张颖,李廷谦,王刚,等.痰热清注射液治疗慢性阻塞性肺疾病急性加重期(痰热阻肺证)的随机对照试验[J].中国循证医学杂志,2004,4(5)：300-305.
[23]刘建博,荆小莉,刘小虹.加味千金苇茎汤对慢性阻塞性肺病急性加重期患者气道清除功能的影响[J].广州中医药大学学报,2006,23(1)：21-24.
[24]崔众,梁直英,董竞成.活血化疲方治疗慢性阻塞性肺疾病急性加重期的临床观察[J].中国中西医结合杂志,2005,25(4)：327-329.
[25]林育华.活血化淤法治疗慢阻肺95例临床观察[J].新中医,1998,30(2)：33-34.
[26]孙志佳.活血祛淤法治疗慢性阻塞性肺疾病理论依据及临床应用[J].陕西中医,2005,26(4)：341-342.
[27]王胜,张念志,季红燕,等.益肺健脾中药对慢性阻塞性肺疾病气道炎症作用的研究[J].中国中西医结合杂志,2002,22(6)：462.
[28]刘小虹,刘琼.培土生金法在慢性阻塞性肺疾病缓解期的床用研究[J].新中医,2002,34(10)：18.
[29]汤翠英,林琳,许银姬.培土生金法对慢阻肺稳定期患者生存质量的影响[J].福建中医药,2006：35(5)：1-4.
[30]张炜,毕小利,史苗颜,等.补肺益肾胶囊对慢性阻塞性肺疾病防治作用的研究[J].中国中医基础医学杂志,2004,10(1)：57.
[31]吴晓晖,徐俭朴.百令胶囊治疗肺肾两虚证慢性阻塞性肺病50例[J].实用中医内科杂志,2004,18(4)：351-352.
[32]耿宏伟,胡秀红.金水宝胶囊治疗慢性阻塞性肺疾病60例[J].中医研究,2003 13(4)：46.
[33]Barns PJ. Chronic obstructive pulmonary disease.N Engl J Med 2000;343:269-280.
[33]Altose MD. Approachs to slowing the progression of COPD. Curr Opin Pulm Med 2003;9:125-130.
[34]Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, et al.Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease, Am J Respir Cirt Care Med 2001;163:1087-1092.
[35]MahlerDA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmetero xinafoate in the treatmenty of COPD. Chest 1999; 115:957-965.
[36]Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaked-agonist, and the combination of all three in patients with COPD. Chest 1994;105:1089-1094.
[37]COMBIVENT Inhalation Awrosol Study Group.In chronic obstructive pulmonary disease, a combination of iprtropium and albuterol is more effective than either agent alone An 85-day multicentre trial. Chest 1994; 105:1411-1419.
[38]Wesseling G, Mostert R, Wouters EEM. A comparison of the effects of anticholinergic and beta2-agonist and combination therapy on respiratory impedence in COPD. Chest 1992:101:166-173.
[39]Maesen FPV, Smeets JJ, Costongs MAL, Wald FDM, Coneliseen PJG. Ba 679 Br, a new long-acting antimuscarinic bronchiodilator:a plot disc-esealation study in COPD. Eur Rtespir J 1993:6:1031-1036.
[40]Ress PJ. Tiotropium in the management of chronic obstructive pulmonary disease. Eur Rtespir J2002; 19:205-206.
[41]Birring SS, Brightling CE, Bradding P, et al. Clinical,radiologic,and induced sputum features of chronic obstructive pulmonary disease in nonsmokers:a descriptive study. Am J Respir Cirt Care Med 2002; 166:1078-1083.
[42]Kanner RE, Connett JE, Williams DE, et al. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disese;The Lung Heath Study.Am J Med 1999; 106:410-416.
[43]Smith KR. National burden of disease in India from indoor air pollution.Proc Natl Acad Sci USA 2000; 97:13286-13293.
[44]ShapiroSD. Elastolytic metalloproteinases produced by human mononuclear phago cytes. Potential roles in destructive lung disease. Am J Respir Cirt Care Med 1994; 150:S160-164
[45]Finlary GA, Russell KJ, McMahon KJ, D'arcy EM, Masterson JB, FitzGerald MX, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorac 1997; 52:502-506.
[46]Dehuijzen PN, Aben KK, Dekker I, Aarts LP, Wielders PL,van Herwaarden CL, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstrucetive pulmonary disease. Am J Respir Cirt Care Med 1996; 154:813-816.
[47]Paredi P,Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxi dation, is elevated in chronic obstructive pulmonary desease. Am J Respir Cirt Care Med 2000; 162:369-373.
[48]Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Cirt Care Med 2000; 162:1175-1177.
[49]Pratico D, Basili S, Vieri M, Cordova C, Violi F,Fitzgerald GA. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Cirt Care Med 1998; 158:1709-1714.
[50]O'Donohue WJ Jr. Oxygen therapy in pulmonary rehabilitation. In Hodgkin JE, Celli BR, Connors GL, eds. Pulmonary Rehabilitation:Guidelines to Success. Lippincott Williams and Willkins; 2000:135-146.
[51]Report of the Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1:681-686.
[52]CooperJD. The history of surgical procedures for emphysema. Ann Thorac Surg 1997;63:312-319.
[53]Martinez FJ. Surgical Therapy for COPD. In Hodgkin JE, Celli BR, Connors GL, eds. PulmonaryRehabilitation:Guidelines to Success. Lippincott Williams and Willins,2000:415-451.
[54]Meyers BF, Patterson GA. Chronic obstructive pulmonary disease. lO.Bullectomy, lung volume reduction surgery and transplantation for patients with chronic obstructive pulmonary disease. Thorax 2003;58:634-638.
[55]Edelman JD, Kotloff RM. Surgical approaches to advanced emphysema. Respir Care Clin N Am 1998;4:513-539.
[56]Russi EW, Stammberger U, Weder W. Lung volume reduction surgery for emphysema. Eur Respir J 1997; 10:208-218.
[57]Fessler HE, Permutt S. Lung volume reduction surgery and airflow limitation. Am J Respir Cirt Care Med 1998; 157:715-722.
[58]Gelb AF, Mckenna RJ Jr, Brenner M, Epstein JD, Zamel N. Lung function 5 yr after lung volume reduction surgery for emphy sema. Am J Respir Cirt Care Med 2001; 163:1562-1566.
[59]Mehran RJ, Deslauriers J. Indications for surgery and patient work-up for bullectomy. Chest Surg Clin N Am 1995; 5:717-734.
[60]Trulock EP. Lung transplantation. Am J Respir Cirt Care Med 1997; 155:789-818.
[61]Cassivi SD, Meyers BF, Battafarano RJ, et al. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg 2002; 74:1663-1669.
[62]Barnes PJ. Inhaled corticosteroida are not beneficial in chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2000; 161:341-344.
[63]Calverley PM. Inhaled corticosteroida are beneficial in chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2000; 161:341-342.
[64]Barnes PJ. New treatments for COPD. Nat Rev Drug Discov 2002; 1:437-446.
[65]Barnes PJ. Therapy of chronic obstructive pulmonary disease. Pharmacol Ther 2003; 97:87-94.
[66]HanselTT, BarnesPJ, eds. New Drugs forAsthma, Allergy and COPD. Basel:Karger,2001.
[67]Huang Z, Ducharme Y, MacDonald D, Robichhaud A. The next generation of PDEA inhibitors. Curr OPin Chem Biol 2001; 5:432-438.
[68]Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001:108:671-680.
[69]Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109:288-295.
[70]Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG. Fully human anti-interleukin-8 monoclonal antibodies:potential therapeutice for the treatment of inflammatory disease states. J Leukoc Biol 1999; 66:401-410.
[71]De Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Cirt Care Med 1996; 153:633-637.
[72]Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Cirt Care Med 1996;153:1530-1535.
[73]Pulmonary rehabilitation-1999. American Thoracic Society. Am J Respir Cirt Care Med 1999;159:1666-1682.
[74]Pulmonary rehabilitation. Thorax.2001; 56:827-834.
[75]Buist AS, Sullivan SD, Weiss K, eds. Measurement and evaluation of outcomes in COPD. Eur Respir J 2003;21(Suppl):153s.
[76]Berry MJ, Rejeski WJ, Adair NE, Zaccaro D. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Cirt Care Med 1999; 160:1248-1253.
[77]Miller WF. Historical perspective of pulmonary rehabilitation. In Hodgkin JE, Celli BR, Connors GL, eds. Pulmonary Rehailitation:Guidelines to Success. Baltimore, MD:Lippincott Williams and Wilkins,2000:1-20.
[78]Bott J, Agent P, Callaghan S. Physiotherapy and nursing during non-invasive positive pressure. In Simonds AK, ed. Non-invasive Respiratory Support:a Practical Handbook.New York:Arnold,2001:230-254.
[79]JonesCE, Chan K. Interleukin-17 Stimulates the Expression oflnterleukin-8, Grouth-Related, Oncgeue-a, andGranulocyte-Colony-Stimulating Factor byHuman Airway EpithelialCells [J]. Am JRespirCellMolBiol,2002,26(3):748-753.
[80]Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest,1997; 112(2):505-510.
[81]朱斌,郝建,王伟,等慢性阻塞性肺疾病患者血清细胞因子的变化及其临床意义[J].临床肺科杂志.2008：(12)：17-19.
[82]刘洪,张弛,陈云凤,等.慢性阻塞性肺疾病炎症细胞因子与肺通气功能变化相关分析[J].实用医院临床杂志,2007：1(1)：36-37.
[83]蔡志明.慢性阻塞性肺部疾病-机制的新发展[J].中华内科杂志,2000,39(3)：204-206.
[84]Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med,2007; 176(6):532-555.
[85]丁艳苓.白三烯B4与肺部疾病[J].临床内科杂志,2005,22(11)：790-792.
[86]国家体育总局健身气功管理中心编健身气功·易筋经第一版人民体育出版社,2003.7.
[87]国家体育总局健身气功管理中心编健身气功·八段锦第一版人民体育出版社,2003.7.
[88]国家体育总局健身气功管理中心编健身气功·六字诀第一版人民体育出版社,2003.7.
[89]国家体育总局健身气功管理中心编健身气功·五禽戏第一版人民体育出版社,2003.7.
[90]王震,邱丕相,李志明.从导引图与养生功法的流变探研中国健身气功的本质特征[J].体育科学,2005 25(7)：26-28.
[91]朱毅,李凝,金宏柱.五禽戏早期干预对稳定期慢性阻塞性肺疾病患者的影响[J].辽宁中医药大学学报,2010：6(12)：53-54.
[92]崔永胜,虞定海.“健身气功·五禽戏”锻炼对中老年女性身心健康的影响[J].北京体育大学学报,2004：11(27)：61-63.
[93]陈锦秀,邓丽金.传统“六字诀呼吸操”对COPD稳定期患者的康复效果[J].中国康复医学杂志,200924(10)：32-35.
[94]王振伟,杨佩兰,汤杰等.“六字诀”对慢性阻塞性肺疾病患者生活质量及中医证候的影响[J].上海中医药杂志,2010;44(5)：48.
[95]陈锦秀.传统六字诀呼吸操对慢性阻塞性肺疾病稳定期患者生活质量的效果研究[J].中国自然医学杂志,2009;12(11)：37-38.
[96]冯毅卿,潘华山,泣希等.八段锦运动对慢性阻塞性肺病稳定期老年患者的疗效观察[J].新中医,2009：8(41)：52.
[97]潘华山.八段锦运动负荷对老年人心肺功能影响的研究[J].新中医,2008;1(40)：23-25.
[98]杜少武,章文春,周美芳.健身气功·易筋经锻炼对中老年人体质的影响程度[J].北京体育大学学报,2006：11(29)：39-41.
[99]项汉平,刘树军,贾海等.浅析健身气功易筋经功法特点对呼吸肌的作用[J].北京体育大学学报2006：1(25)：32-35.
[100]冯毅卿,潘华山.八段锦运动对慢性阻塞性肺病稳定期老年患者的疗效观察[J].新中医,2010：5(62)：71.
[101]Clark CJ, Cochrane LM, Mackay E, Paton B. Skeletal muscle strength and endurance in patients with mild COPDand the effects of weight training. Eur Respir J 2000; 15:92-97.
[102]Ortega F, Toral J, Cejudo P, et al. Comparison of effects of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2002; 166:669-674.
[103]Jenkins SC, Heaton RW, Fulton TJ, Moxham J. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest 1987;91:804-807.
[104]Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmetero xinafoate in the treatmenty of COPD. Chest 1999; 115:957-965.
[105]Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmetero xinafoate in the treatmenty of COPD. Chest 1999; 115:957-965.
[106]Suzuki S, Watanuki Y, Yoshiike Y, Okubo T. Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease. Thorax 1997;52:125-129.
[107]Johnson M. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol 2002; 110(Suppl 6):S282-290.
[108]AdcockIM, ManeechotesuwanK, UsmaniO. Molecular interactions between glucocorticoids and long-acting beta2-agonists.J Allergy Clin Immunol 2002; 110(Suppl 6):S261-268.
[109]Mahler DA, The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002; 110(Suppl 6):S298-303.
[110]Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112:336-340.
[111]Guhan AR, Cooper S, Oborne J, Lewis S, Bennett A, Tattersfield AE. Systemic effects of formoterol and salmeterol:a dose-response comparison in healthy subjects.Thorax 2000;55:650-656.
[112]Calverley PM. Inhaled corticosteroida are beneficial in chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2000; 161:341-342.
[113]Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patient after regular use of fluticasone propionate and salmeterol in general practice. Eur Rtespir J 2002;20:819-825.
[114]Sin DD, Tu Inhald corticostercids and the risk of mortility and readmission in elderly patients with chronic obstructibe pulmonary disease. Am J Respir Cirt Care Med 2001;164:341-345.
[115]Barnes PJ. Inhaled corticosteroida are not beneficial in chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2000; 161:341-344.
[116]Rennard SI. COPD:treatments benefit patients.Lancet 2003; 361:444-445.
[117]Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Heath Study Am J Respir Crit Care Med2000,161:381-390.
[118]Fletcher C, Peto R, Tinker CM, Speizer FE. The Natural History of Chronic Bronchitis and Emphysema. New York:Oxford University Press.1976.
[119]Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic ob structive pulmonary disease:the ISOLDE trial. Br Med J 2000;320:1297-1303.
[120]Rochester CL. Exercise training in chronic obstructive pulmonarydisease[J]. Journal of Rehabilitation Research and Development2003,40(5):59-80.
[121]Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacitydynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med2001,163:1395-1399.
[122]Ortega F, Montemayor T, Sanchez A, et al. Role of cardiopulmonary exercise testing and the criteria used to determine disability in patients with severe chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,1994,150(3):747.
[123]Jones PW, Mahler DA. Key outcomes in COPD:heslth-related quality of life. Proceedings of an expert round table held July 20-22,2001,Boston Massachusetts, USA. Eur Respir Rev 2002;12.
[124]Engstrom CP, Presson LO, Larsson S, Sullivan M. Health-relate quality of life in COPD:why both disease-specific and generic measures should be used. Eur Respir J 2001;18:69-76.
[125]Jones PW, Quirk FH, Baveystock CM. The St Grorge's Respiratour Qudetionnaire. Respir Med 1991:85:25-31.
[126]方宗君,蔡映云,蒋浩明,等.SGRQ问卷对慢性阻塞性肺疾病患者生命质量的评估研究[J].中国行医学科学,1996,5：16-17.
[127]陆慰首,张一杰,胡波,等.应用St Gcorgecs呼吸问卷评估我国慢性阻塞性肺疾病患者生存质量的价值[J].华结核和呼吸杂志,2003,26：195-198.
[128]王秋月,王伟等.慢性阻塞性肺疾病患者生活质量及其影响因素分析[J].中华结核和呼吸杂志,2003,12：811-812.
[129]王永兴,应延风.慢性阻塞性肺疾病患者生存质量与肺功能的关系[J].中国临床康复,2002,19：2851-2852.
[130]Belman MJ.Exercise in patients with chronic obstructive pulmonary disease. Thorax 1993;48:436-446.
[131]Mulloy E, McNicholas WT. Ventilation and gas exchange during sleep and exercise in severe COPD. Chest 1996; 109:387-394.
[132]Suzuki S, Watanuki Y, Yoshiike Y, OkuboT. Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease.Thorax 1997;52:125-129.
[133]Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillessen A, et al. Resperatory viruses in exacerbations of chronic obstructive pulmonary disease sequiring hospitalization:a case-control study. Thorax.2003; 58:37-42.
[134]Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med.2001; 134:595-599.
[135]Guhan AR, Cooper S, Oborne J, Lewis S, Bennett A, Tattersfield AE. Systemic effects of formoterol and salmeterol:a dose-response comparison in healthy subjects. Thorax 2000;55:650-656.